Drozapol-Profil S.A.

As of September 30, 2024, Drozapol-Profil S.A. has 5.37M shares outstanding.

These figures are as of September 30, 2024. The price-to-sales ratio is 0.38, and the price-to-book ratio stands at 0.47.

These figures are as of September 30, 2024. The EV/Sales ratio of 0.11 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Drozapol-Profil S.A. trades at an EV/FCF ratio of 0.79, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of September 30, 2024, Drozapol-Profil S.A. maintains a current ratio of 3.62, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended September 30, 2024, Drozapol-Profil S.A. posted a negative return on equity (ROE) of -7.59, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -4.70, reflecting losses generated across the asset base. Inventory turnover of 2.95 indicates how many times Drozapol-Profil S.A. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended September 30, 2024, Drozapol-Profil S.A. posted a gross margin of 8.19, reflecting its pricing power and cost economics. The operating margin of -2.40 and net profit margin of -6.39 provide insight into operational efficiency.

These figures cover the twelve months ended September 30, 2024. Free cash flow yield stands at 35.26, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 6.64, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Drozapol-Profil S.A. shareholders.

Drozapol-Profil S.A.'s most recent stock split took place on November 19, 2014 with a 5:1 split ratio.

As of September 30, 2024, Drozapol-Profil S.A. has an Altman Z-Score of 2.27, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.